About Zinc finger protein 613
Zinc finger protein 613 (ZNF613) is a protein
from Homo sapiens identified by UniProt accession
Q6PF04, 617 residues long.
MolForge cross-references it against 0 known binders and
4 disease associations.
Target properties
| Protein name | Zinc finger protein 613 |
|---|
| UniProt accession | Q6PF04 |
|---|
| Gene | ZNF613 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 617 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (4)
Diseases linked to this target (Open Targets).
- cancer · score 0.00
- hepatocellular carcinoma · score 0.00
- insulin resistance · score 0.00
- ulcerative colitis · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6PF04-F1 | alphafold | PREDICTED | 66.44 | — |
Amino-acid sequence (617 residues)
MIKSQESLTL EDVAVEFTWE EWQLLGPAQK DLYRDVMLEN YSNLVSVGYQ ASKPDALFKL EQGEPWTVEN EIHSQICPEI KKVDNHLQMH SQKQRCLKRV EQCHKHNAFG NIIHQRKSDF PLRQNHDTFD LHGKILKSNL SLVNQNKRYE IKNSVGVNGD GKSFLHAKHE QFHNEMNFPE GGNSVNTNSQ FIKHQRTQNI DKPHVCTECG KAFLKKSRLI YHQRVHTGEK PHGCSICGKA FSRKSGLTEH QRNHTGEKPY ECTECDKAFR WKSQLNAHQK IHTGEKSYIC SDCGKGFIKK SRLINHQRVH TGEKPHGCSL CGKAFSKRSR LTEHQRTHTG EKPYECTECD KAFRWKSQLN AHQKAHTGEK SYICRDCGKG FIQKGNLIVH QRIHTGEKPY ICNECGKGFI QKGNLLIHRR THTGEKPYVC NECGKGFSQK TCLISHQRFH TGKTPFVCTE CGKSCSHKSG LINHQRIHTG EKPYTCSDCG KAFRDKSCLN RHRRTHTGER PYGCSDCGKA FSHLSCLVYH KGMLHAREKC VGSVKLENPC SESHSLSHTR DLIQDKDSVN MVTLQMPSVA AQTSLTNSAF QAESKVAIVS QPVARSSVSA DSRICTE
Explore Zinc finger protein 613 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets